Aurobindo is set to expand its European footprint, “particularly in the generics market of Eastern Europe”, by signing a definitive agreement to acquire for €74 million (US$87 million) in cash Apotex’ businesses in five countries: Belgium, the Czech Republic, the Netherlands, Poland and Spain. Slated to close in the next three-to-six months, the acquisition is subject to clearance by Dutch and Polish competition authorities. Apotex intends to “focus its resources on the Americas, where strong demand for its portfolio continues”.
Aurobindo buys Europe operations from Apotex
Aurobindo is set to expand its European footprint, “particularly in the generics market of Eastern Europe”, by signing a definitive agreement to acquire for €74 million (US$87 million) in cash Apotex’ businesses in five countries: Belgium, the Czech Republic, the Netherlands, Poland and Spain. Slated to close in the next three-to-six months, the acquisition is subject to clearance by Dutch and Polish competition authorities. Apotex intends to “focus its resources on the Americas, where strong demand for its portfolio continues”.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.
• By
Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.
• By
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
More from Generics Bulletin
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.